Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesPrevention of vertebral fractures in osteoporosis: Mixed treatment comparison of bisphosphonate therapies
Current Medical Research and Opinion, 06/25/09
Jansen JP et al. - Data indicate that zoledronic acid provides a greater vertebral fracture risk reduction in postmenopausal women with osteoporosis than ibandronate, alendronate, or risedronate.
Methods- A comparison of the efficacy of bisphosphonates in prevention of vertebral fractures in postmenopausal women with osteoporosis
- 7 randomized placebo controlled trials investigating the effects of:
- Zoledronic acid (1 study)
- Alendronate (3 studies)
- Ibandronate (1 study), and
- Risedronate (2 studies)
- on fractures with a f/u of 3 yrs were identified
- Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison (MTC)
- Zoledronic acid shows the greatest reduction in vertebral fractures of all four bisphophonates compared
- It showed an OR of 0.28 vs placebo, an OR of 0.57 vs ibandronate, an OR of 0.54 vs alendronate, and OR of 0.49 vs risedronate
- Alendronate, ibandronate, and risedronate showed comparable vertebral fracture reductions
- Indirect comparisons using a conservative random effects model supported these findings
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoporosis risk assessment and ethnicity
Journal of General Internal Medicine, 12/07/09
Hormonal deprivation therapy-induced osteoporosis in postmenopausal women with breast cancer
Best Practice & Research: Clinical Rheumatology, 12/07/09
Monitoring osteoporosis treatment
Best Practice & Research: Clinical Rheumatology, 12/04/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes
Evidence-Based Medicine, 12/07/09
In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status
Evidence-Based Medicine, 12/07/09
The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 12/04/09
Sponsor
Article Search
Sponsor